Abbott, DexCom settle patent disputes
By HME News Staff
Updated 12:22 PM CST, Thu January 2, 2025
SAN DIEGO and ABBOTT PARK, Ill. – DexCom and Abbott Diabetes Care have entered into a settlement and patent cross license agreement to resolve all outstanding patent litigation between the parties related to their continuous glucose monitors, according to a Form 8-K filed by Dexcom with the U.S. Securities and Exchange Commission. Both companies have accused the other of infringing certain patents and each company has filed counterclaims and actions to invalidate the other’s patents. Under the agreement, DexCom has granted Abbott and its affiliates, and Abbott and its affiliates have granted DexCom and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and patent applications relating to analyte sensing. The agreement does not obligate DexCom or Abbott to pay any royalties or any other form of financial compensation. Also as part of the agreement, both companies have agreed not to litigate patent, trade dress and design rights disputes with each other for the next 10 years. “Abbott considers this agreement a positive development as it allows the company to fully focus on supporting people with diabetes with its technologies and services,” the company stated in a press release.
Comments